BIOCRYST PHARMACEUTICALS INC (BCRX)

US09058V1035 - Common Stock

5.87  +0.08 (+1.38%)

After market: 5.8 -0.07 (-1.19%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
17.8M
-63.52%
157.2M
783.15%
270.8M
72.26%
334.37M
23.47%
EBITDA
YoY % growth
-174.05M
-76.20%
-176.92M
-1.65%
-146.96M
16.93%
-99.314M
32.42%
N/AN/AN/AN/AN/A
EBIT
YoY % growth
-174.8M
-75.68%
-177.7M
-1.66%
-148.4M
16.49%
-85.201M
42.59%
Operating Margin
-982.02%-113.04%-54.80%-25.48%
EPS
YoY % growth
-1.08
-10.20%
-1.03
4.63%
-1.33
-29.13%
-1.08
18.57%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth
-0.25
34.51%
Revenue
Q2Q % growth
91.807M
15.41%
EBITDA
Q2Q % growth
-42.07MN/AN/AN/AN/A
EBIT
Q2Q % growth
-19.441M
58.02%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth
-0.28
26.32%
-0.25-0.03-12.50%
Q3 2023
Q2Q % growth
-0.19
17.39%
-0.240.0520.19%
Q2 2023
Q2Q % growth
-0.24
25.00%
-0.23-0.01-3.06%
Q1 2023
Q2Q % growth
-0.28
30.00%
-0.300.028.14%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
86.74M
14.39%
87.673M-933K-1.06%
Q2 2023
Q2Q % growth
82.49M
25.88%
82.606M-116K-0.14%
Q1 2023
Q2Q % growth
68.78M
37.78%
73.111M-4.331M-5.92%
Q4 2022
Q2Q % growth
79.55M
68.68%
77.149M2.401M3.11%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -8.35% 0% 3.77%
Revenue0% 0.06% 0% 0.14%